71 related articles for article (PubMed ID: 12647551)
1. [Interstitial boost and altered fractionation as novel approaches to dose escalation in the radiotherapy of glioblastoma multiforme].
Mangel L; Julow J; Major T; Hável J; Lövey J; Viola A; Somogyi A; Németh G
Orv Hetil; 2003 Feb; 144(5):223-9. PubMed ID: 12647551
[TBL] [Abstract][Full Text] [Related]
2. [The possibilities of fractionated external beam repeat irradiation of relapsed primary brain tumours: the first Hungarian experience].
Mangel L; Sipos L; Fedorcsák I; Viola A; Julow J; Bajcsay A; Németh G; Fodor J
Orv Hetil; 2007 Sep; 148(39):1843-9. PubMed ID: 17890172
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution.
Hulshof MC; Koot RW; Schimmel EC; Dekker F; Bosch DA; González González D
Strahlenther Onkol; 2001 Jun; 177(6):283-90. PubMed ID: 11446316
[TBL] [Abstract][Full Text] [Related]
4. CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results.
Tselis N; Kolotas C; Birn G; Röddiger S; Filipowicz I; Kontova M; Fountzilas G; Selviaridis P; Baltas D; Heyd R; Anagnostopoulos G; Zamboglou N
Strahlenther Onkol; 2007 Oct; 183(10):563-70. PubMed ID: 17896088
[TBL] [Abstract][Full Text] [Related]
5. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Roddiger SJ; Kolotas C; Filipowicz I; Kurek R; Kuner RP; Martin T; Baltas D; Rogge B; Kontova M; Hoffmann G; Pollow B; Zamboglou N
Strahlenther Onkol; 2006 Jan; 182(1):22-9. PubMed ID: 16404517
[TBL] [Abstract][Full Text] [Related]
7. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study.
Welsh J; Sanan A; Gabayan AJ; Green SB; Lustig R; Burri S; Kwong E; Stea B
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):159-65. PubMed ID: 17331666
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy of malignant gliomas: results from conventional treatment methods and the prospects of advanced techniques.
Rubino G; Sacco P; Cerase A; Volterrani L; Sebaste L; Pepi F; Pirtoli L
Radiol Med; 2004; 107(1-2):128-35. PubMed ID: 15031704
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
[TBL] [Abstract][Full Text] [Related]
10. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
11. Definitive radiotherapy based on HDR brachytherapy with iridium 192 in uterine cervix carcinoma: report on the Vienna University Hospital findings (1993-1997) compared to the preceding period in the context of ICRU 38 recommendations.
Pötter R; Knocke TH; Fellner C; Baldass M; Reinthaller A; Kucera H
Cancer Radiother; 2000; 4(2):159-72. PubMed ID: 10812362
[TBL] [Abstract][Full Text] [Related]
12. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
13. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.
Nieder C; Nestle U; Ketter R; Kolles H; Gentner SJ; Steudel WI; Schnabel K
Radiat Oncol Investig; 1999; 7(1):36-41. PubMed ID: 10030622
[TBL] [Abstract][Full Text] [Related]
14. [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure.
Douglas JG; Stelzer KJ; Mankoff DA; Tralins KS; Krohn KA; Muzi M; Silbergeld DL; Rostomily RC; Scharnhorst J; Spence AM
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):886-91. PubMed ID: 16242251
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of hemoglobin level prior to radiotherapy on survival in patients with glioblastoma.
Odrazka K; Petera J; Kohlova T; Dolezel M; Vaculikova M; Zouhar M; Malek V; Hobza V; Latr I; Nemecek S; Sercl M; Ryska P; Blaha M; Cermakova E
Strahlenther Onkol; 2003 Sep; 179(9):615-9. PubMed ID: 14628127
[TBL] [Abstract][Full Text] [Related]
16. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept.
Fokdal L; Tanderup K; Nielsen SK; Christensen HK; Røhl L; Pedersen EM; Schønemann NK; Lindegaard JC
Radiother Oncol; 2011 Sep; 100(3):473-9. PubMed ID: 21924784
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated external beam radiotherapy to boost the prostate with ≥85 Gy/equivalent dose for patients with localised disease at high risk of lymph node involvement: feasibility, tolerance and outcome.
Zilli T; Jorcano S; Escudé L; Linero D; Rouzaud M; Dubouloz A; Miralbell R
Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):316-22. PubMed ID: 24667210
[TBL] [Abstract][Full Text] [Related]
18. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation.
Tralins KS; Douglas JG; Stelzer KJ; Mankoff DA; Silbergeld DL; Rostomily RC; Hummel S; Scharnhorst J; Krohn KA; Spence AM
J Nucl Med; 2002 Dec; 43(12):1667-73. PubMed ID: 12468518
[TBL] [Abstract][Full Text] [Related]
19. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?
Morton G; Loblaw A; Cheung P; Szumacher E; Chahal M; Danjoux C; Chung HT; Deabreu A; Mamedov A; Zhang L; Sankreacha R; Vigneault E; Springer C
Radiother Oncol; 2011 Sep; 100(3):463-7. PubMed ID: 21924511
[TBL] [Abstract][Full Text] [Related]
20. Postoperative radiotherapy of glioblastoma multiforme: analysis and critical assessment of different treatment strategies and predictive factors.
Piroth MD; Gagel B; Pinkawa M; Stanzel S; Asadpour B; Eble MJ
Strahlenther Onkol; 2007 Dec; 183(12):695-702. PubMed ID: 18040615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
